Sleep apnea

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
Martedì, Aprile 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

AdaptHealth Appoints Suzanne Foster as Chief Executive Officer

Retrieved on: 
Mercoledì, Aprile 17, 2024
Nursing, Medical Supplies, Health, Medical Devices, Practice Management, Managed Care, Cardiology, Health policy, Danaher Corporation, Chairperson, Cardinal Health, Diabetes, History, Obesity, JD, Sleep apnea, Suffolk University Law School, Stanley Black & Decker, Harvard University, Growth, Management

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer.
  • Ms. Foster will assume leadership of the Company from interim CEO and Chairman of the Board, Richard Barasch, on May 20, 2024.
  • Ms. Foster holds an MPH in Law and Health Policy from Harvard University and a JD from Suffolk University Law School.
  • We are grateful for his dedication to AdaptHealth and know he is delivering a healthy business to Suzanne.

Global Oxygen Cylinders and Concentrators Market Analysis and Forecasts, 2020-2024 and 2025-2030: Internet of Things (IoT) Connectivity Transforms Oxygen Concentrators into Smart Healthcare Devices - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Aprile 11, 2024
Health, Medical Supplies, Medical Devices, USD, Epidemiology, Internet of things, Porter's five forces analysis, Miniaturization, Investment, Chronic obstructive pulmonary disease, SWOT, Skin, Death, Health care, Vital signs, Patient safety, Mask, Incidence, Sleep apnea, Patient, Asthma, Prevalence, IHME, Medication, COPD, Medical device

The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.

Key Points: 
  • The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.
  • The Oxygen Cylinders and Concentrators Market is expected to continue growing as the global population ages and the prevalence of respiratory diseases increases, driving the need for effective oxygen therapy solutions.
  • As the global population ages and environmental factors contribute to respiratory health issues, the need for oxygen cylinders and concentrators continues to grow.
  • Technological advancements in portable oxygen cylinders and concentrators have transformed respiratory care, offering greater convenience, mobility, and usability for patients.

Known for Affordable Oral Health Care, Elegant Smiles is Offering a New High-Tech AI Dental Patient Experience

Retrieved on: 
Giovedì, Aprile 25, 2024
Dental care, Orthodontics, AI, Dentistry, Partnership, Artificial intelligence, Dentist, Environment, Sleep apnea, Patient, Multimedia, Health, Pediatric dentistry

ATLANTA, April 25, 2024 /PRNewswire-PRWeb/ -- Elegant Smiles is excited to announce a groundbreaking partnership with the leader in dental AI and computer vision solutions, Pearl Inc. http://www.hellopearl.com. The AI (artificial intelligence) solutions Pearl delivers can assist dental professionals by identifying issues earlier and with higher precision, improving diagnostic accuracy by almost 95%. With proprietary AI x-ray analysis capabilities, Pearl is able to analyze AI-detected evidence in patient radiographs and integrate it with treatment data from practice management systems, bringing consistency and confidence to the dental industry and the patients it serves. Pearl's computer vision systems identify and evaluate the widest range of pathologic and restorative features detectable in radiographic and 3D dental imaging. With the integration of Pearl's AI-powered clinical insight solutions, Elegant Smiles will be at the forefront of utilizing pioneering technology to enhance patient care. This partnership will allow them to provide consistent and accurate diagnoses, leading to better treatment outcomes for patients.

Key Points: 
  • The team is thrilled to utilize this dental innovation and offer patients unbiased, objective and standardized dental care that they know they can trust.
  • ATLANTA, April 25, 2024 /PRNewswire-PRWeb/ -- Elegant Smiles is excited to announce a groundbreaking partnership with the leader in dental AI and computer vision solutions, Pearl Inc. http://www.hellopearl.com .
  • The AI (artificial intelligence) solutions Pearl delivers can assist dental professionals by identifying issues earlier and with higher precision, improving diagnostic accuracy by almost 95%.
  • With the integration of Pearl's AI-powered clinical insight solutions, Elegant Smiles will be at the forefront of utilizing pioneering technology to enhance patient care.

IDTechEx Examines the Opportunities for Wearables in Digital Health

Retrieved on: 
Venerdì, Aprile 19, 2024
FDA, Sleep apnea, Omron, Sleep disorder, Food, Travel, Health, Dexcom, Diabetes, CGM, Respiratory rate, Medtech, Artificial intelligence, Intelligence, Artificiality, Samsung Galaxy Watch, Digital health, Patient, Electronics, Movement, Metabolism, Athlete, Quality of life, Sleep

IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.

Key Points: 
  • IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.
  • The IDTechEx report on digital health discusses opportunities for consumer health wearables, including key value propositions and a roadmap for wearable sensor technology segmented by key biometrics.
  • IDTechEx's report on digital health covers the intersection of the digital health, diabetes, and consumer markets and includes a 10-year forecast for the CGM market from 2024 – 2034.
  • The consumer health wearables narrative is only one of several stories that IDTechEx covers in " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ".

IDTechEx Examines the Opportunities for Wearables in Digital Health

Retrieved on: 
Venerdì, Aprile 19, 2024
FDA, Sleep apnea, Omron, Sleep disorder, Food, Travel, Health, Dexcom, Diabetes, CGM, Respiratory rate, Medtech, Artificial intelligence, Intelligence, Artificiality, Samsung Galaxy Watch, Digital health, Patient, Electronics, Movement, Metabolism, Athlete, Quality of life, Sleep

IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.

Key Points: 
  • IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.
  • The IDTechEx report on digital health discusses opportunities for consumer health wearables, including key value propositions and a roadmap for wearable sensor technology segmented by key biometrics.
  • IDTechEx's report on digital health covers the intersection of the digital health, diabetes, and consumer markets and includes a 10-year forecast for the CGM market from 2024 – 2034.
  • The consumer health wearables narrative is only one of several stories that IDTechEx covers in " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ".

CPAP Liquidators Introduces Enhanced Travel CPAP Solutions for Sleep Apnea Patients Nationwide

Retrieved on: 
Giovedì, Aprile 11, 2024
Travel, Flexible, Health, Life, Continuous positive airway pressure, Flexible spending account, FSA, Sleep apnea, Pressure, Patient, Health savings account, Work, HSA, Transcend, Sleep, CPAP, Pharmaceutical industry

WALNUT GROVE, Minn., April 11, 2024 /PRNewswire/ -- CPAP Liquidators, a leading supplier of CPAP equipment, is thrilled to unveil an expanded lineup of travel CPAP machines, catering to the needs of sleep apnea patients seeking convenient and reliable therapy options on the go.

Key Points: 
  • WALNUT GROVE, Minn., April 11, 2024 /PRNewswire/ -- CPAP Liquidators, a leading supplier of CPAP equipment, is thrilled to unveil an expanded lineup of travel CPAP machines, catering to the needs of sleep apnea patients seeking convenient and reliable therapy options on the go.
  • An essential aspect of CPAP Liquidators' travel CPAP solutions is their compatibility with Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA), enabling customers to utilize pre-tax funds for their sleep therapy equipment purchases.
  • This feature underscores CPAP Liquidators' commitment to affordability and accessibility, ensuring that individuals can access essential CPAP solutions without financial barriers.
  • Furthermore, CPAP Liquidators is committed to providing excellent customer service and support to all individuals who rely on CPAP therapy for their sleep apnea treatment.

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Retrieved on: 
Martedì, Aprile 9, 2024
Research, CARE, OSA, Health, Sleep apnea, Conditional sentence, Obstructive sleep apnea, Risk, Diabetes, DDS, Patient, Stroke, Sleep, Chronic pain, Quality of life, Heart failure, Therapy, FDA, CMS, Dementia, Pharmaceutical industry

Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.

Key Points: 
  • Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.
  • “Prior to these latest developments, moderate to severe OSA patients on Medicare were relegated almost entirely to a lifetime of some form of CPAP—something most patients find undesirable.
  • Our CARE oral medical devices, on the other hand, can significantly improve and even resolve OSA in about 12 months, with no further intervention required in most cases,” said Kirk Huntsman, Vivos Chairman and Chief Executive Officer.
  • “We are very pleased the Centers for Medicare and Medicaid Services (CMS) recognizes and validates the benefits our FDA cleared devices can have on the lives of patients diagnosed with OSA.

Is Sundown Syndrome Taking Over Your Evenings? Michele Nealon, Psy.D. Shares Expert Tips to Manage the Symptoms

Retrieved on: 
Martedì, Aprile 9, 2024
Health, Agitation, Sleep apnea, Alzheimer's disease, Confusion, Exercise, Chicago school, Hunger, Depression, Caregiver, Diabetes, Empathy, Stroke, Sleep, Mental health, Sundowning, Anxiety, Frustration, Dementia, Medicine, Residential care

Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.

Key Points: 
  • Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.
  • This syndrome's cause is not well understood, but we know it can take a toll on the individual and their caregivers.
  • Setting a schedule of regular exercise, a healthy diet, and quality sleep for you and the person you are taking care of is imperative.
  • Patience and empathy are key when trying to ease their agitation because it can worsen if they sense your frustration.

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Giovedì, Marzo 28, 2024
CARE, Sleep apnea, CPAP, Continuous positive airway pressure, Exercise, Environment, VIP, Obstructive sleep apnea, PAP, Shareholder, Webcast, Patient, DME, Sleep, DNA, ODO, AHI, Messenger, Myotherapy, Security (finance), Danaher Corporation, Clinical trial, Therapy, Annual report, Optimism, Dentist, FDA, Food, Pharmaceutical industry

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of unrelated third parties with non-FDA approved products in the sleep apnea treatment space adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance.
  • Since then, we’ve received high levels of inquiries related to our Vivos CARE products that treat OSA in adults.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .